Using provocative design to foster electronic informed consent innovation.

Clinical study Digital consent Ethics Human-centered design Provotypes Qualitative research User interface

Journal

BMC medical informatics and decision making
ISSN: 1472-6947
Titre abrégé: BMC Med Inform Decis Mak
Pays: England
ID NLM: 101088682

Informations de publication

Date de publication:
17 11 2022
Historique:
received: 17 12 2021
accepted: 03 11 2022
entrez: 18 11 2022
pubmed: 19 11 2022
medline: 22 11 2022
Statut: epublish

Résumé

The development of technological applications in clinical research, such as electronic informed consent (eIC), is on the rise. The involvement of end users throughout the design process of eIC is of utmost importance to improve the current informed consent process. Using a provocative design, we conducted interviews with 30 clinical research participants. Provotypes were used as a starting base to discuss various aspects relevant to eIC. By providing a medium to encourage divergent thinking, participants' views and concerns were solicited. Thematic analysis was undertaken using NVivo. The majority of participants placed trust in the principal investigator or the hospital to perform the role of eIC hosting party. Differing opinions were reported on the amount of information required related to stakeholders' access to an eIC system, and thus, to participants' personal data, to enable trust in an eIC system. Nevertheless, this study indicates a general willingness of participants to share personal data with physicians and pharmaceutical companies on an international level, and to receive requests for new research studies via an eIC system. Participants suggested to tailor an eIC system based upon their preferences, for example, regarding whom they want to share their personal data with. Moreover, they expressed a desire to choose how they can contact the research team, and to indicate which study-related information they would like to receive electronically. In addition, positive opinions were voiced on the integration of a test to assess participants' understanding before providing their eIC. Following a research through design approach, insights have been generated which inform the design of eIC. Provotypes were designed to help participants think beyond what is familiar to them. Study findings revealed that not all situations were perceived as provocative, because of participants' motivation to advance scientific research and the trust they place in the research team. Nevertheless, the use of provocative design resulted in additional insights, generated by clinical research participants, which could be considered in the further design of eIC.

Sections du résumé

BACKGROUND
The development of technological applications in clinical research, such as electronic informed consent (eIC), is on the rise. The involvement of end users throughout the design process of eIC is of utmost importance to improve the current informed consent process.
METHODS
Using a provocative design, we conducted interviews with 30 clinical research participants. Provotypes were used as a starting base to discuss various aspects relevant to eIC. By providing a medium to encourage divergent thinking, participants' views and concerns were solicited. Thematic analysis was undertaken using NVivo.
RESULTS
The majority of participants placed trust in the principal investigator or the hospital to perform the role of eIC hosting party. Differing opinions were reported on the amount of information required related to stakeholders' access to an eIC system, and thus, to participants' personal data, to enable trust in an eIC system. Nevertheless, this study indicates a general willingness of participants to share personal data with physicians and pharmaceutical companies on an international level, and to receive requests for new research studies via an eIC system. Participants suggested to tailor an eIC system based upon their preferences, for example, regarding whom they want to share their personal data with. Moreover, they expressed a desire to choose how they can contact the research team, and to indicate which study-related information they would like to receive electronically. In addition, positive opinions were voiced on the integration of a test to assess participants' understanding before providing their eIC.
CONCLUSIONS
Following a research through design approach, insights have been generated which inform the design of eIC. Provotypes were designed to help participants think beyond what is familiar to them. Study findings revealed that not all situations were perceived as provocative, because of participants' motivation to advance scientific research and the trust they place in the research team. Nevertheless, the use of provocative design resulted in additional insights, generated by clinical research participants, which could be considered in the further design of eIC.

Identifiants

pubmed: 36397108
doi: 10.1186/s12911-022-02039-6
pii: 10.1186/s12911-022-02039-6
pmc: PMC9669523
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

296

Subventions

Organisme : European Union's Horizon 2020 research and innovation programme
ID : 825903

Informations de copyright

© 2022. The Author(s).

Références

BMC Med Ethics. 2021 Jul 31;22(1):108
pubmed: 34332572
BMC Med Res Methodol. 2013 Sep 18;13:117
pubmed: 24047204
NPJ Digit Med. 2021 Feb 26;4(1):40
pubmed: 33637833
Lancet Psychiatry. 2021 May;8(5):347
pubmed: 33887171
J Law Med Ethics. 2018 Mar;46(1):110-118
pubmed: 30057442
Qual Saf Health Care. 2006 Oct;15(5):307-10
pubmed: 17074863
BMC Med Ethics. 2020 Aug 13;21(1):72
pubmed: 32791969
J Med Internet Res. 2016 Apr 15;18(4):e66
pubmed: 27083521
Semin Oncol Nurs. 2011 Aug;27(3):183-91
pubmed: 21783009
BMC Med. 2019 Mar 18;17(1):62
pubmed: 30879466
Comput Struct Biotechnol J. 2019 Mar 25;17:463-474
pubmed: 31007872
J Biomed Inform. 2005 Feb;38(1):75-87
pubmed: 15694887
J Med Internet Res. 2020 Oct 8;22(10):e19129
pubmed: 33030440
BMC Med Ethics. 2018 Sep 15;19(1):79
pubmed: 30219106
Clin Trials. 2017 Apr;14(2):170-179
pubmed: 28166647
JMIR Mhealth Uhealth. 2017 Feb 16;5(2):e14
pubmed: 28209557
J Med Internet Res. 2018 Dec 13;20(12):e11254
pubmed: 30545807
J Med Internet Res. 2018 May 01;20(5):e10235
pubmed: 29716883
MDM Policy Pract. 2019 Mar 28;4(1):2381468319840322
pubmed: 30944886
Eur J Hum Genet. 2021 Apr;29(4):687-698
pubmed: 33408362

Auteurs

Evelien De Sutter (E)

Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. evelien.desutter@kuleuven.be.

Stef Verreydt (S)

Distributed and Secure Software (DistriNet), Department of Computer Science, KU Leuven, Leuven, Belgium.

Koen Yskout (K)

Distributed and Secure Software (DistriNet), Department of Computer Science, KU Leuven, Leuven, Belgium.

David Geerts (D)

KU Leuven Digital Society Institute, KU Leuven, Leuven, Belgium.

Pascal Borry (P)

Centre for Biomedical Ethics and Law, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.

An Outtier (A)

Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.

Marc Ferrante (M)

Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.

Corinne Vandermeulen (C)

Leuven University Vaccinology Centre, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.

Nele Vanmechelen (N)

Department of Endocrinology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.

Bart Van der Schueren (B)

Department of Endocrinology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.

Isabelle Huys (I)

Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH